Go To Global Site
Welcome to UCB in the United States

Feb

27

Our Continued Commitment to Patients, Including Those with Rare Diseases

This Rare Disease Week, we continue to raise awareness about the need for continued innovation and development for rare diseases. At UCB, we have a fundamental commitment to people living with severe diseases, their caregivers, and their families, to help them to live their best lives. This means innovating to bring differentiated solutions with unique outcomes, offering the best individual experience, and ensuring access to all those who need these solutions in a way which is viable for patients, society, and UCB.

Feb

21

Delivering Value for Patients Now and In the Future

Since 2015, our Patient Value Strategy has been the driver of UCB’s approach to delivering value for patients. Our operational model puts patients and their individual experiences at the heart of everything we do – from discovery to development to delivery.

Feb

05

Recognizing Patients Who Inspire Us

At UCB, we innovate to bring differentiated solutions with unique outcomes that help specific patients achieve their goals. To do this, we always start with the patient – listening to their experiences, what they value, and what their needs are – keeping them at the heart of everything we do. In honor of Patient Recognition Week, check out a few stories that inspire us to continue to invest in research, expand our scientific understanding, and deliver solutions that provide patients the best individual experience.

Jan

29

UCB: A Decade in Review

Over the last 10 years, UCB has delivered breakthrough medicines to improve the lives of patients. President and Head of U.S. Operations Duane Barnes, writes about how UCB aspires to innovate for patients over the next decade as we look toward 2030.

Dec

12

UCB’s U.S. Neurology Team Wins EyeForPharma Award for Agile Transformation

(L to R): Members of the U.S. Neurology Internal Engine Stephanie Hunter-Banks, Jim Hlavenka, Brad Chapman, Trenton Merideth, Tonja Pitts

UCB’s U.S. Neurology team won a 2019 EyeForPharma award last night in the “Most Promising Agile Transformation” category, which recognizes an experimental initiative that has the potential to disrupt the status quo. The award was presented for the team’s Internal Engine transformation, fulfilling the award criteria of showing agility through rapid creation of a service that touched real customers before being refined and assessed through smart measurement.

Dec

10

Patient-Driven Approach to Innovation

At UCB, our approach to innovation is designed around the patient and their individual experience. Every day, Chris Protos, Solution Enablement Lead, wakes up and thinks about ways we can continue to keep patients at the heart of everything we do. Hear more from Chris about how we’re addressing gaps in patient care through our patient-driven approach to innovation by watching the video below.

Dec

09

Press Release: UCB Presents Final Results from Phase II Study of Rozanolixizumab in Primary Immune Thrombocytopenia (ITP) at 2019 ASH Annual Meeting

UCB Presents Final Results from Phase II Study of Rozanolixizumab in Primary Immune Thrombocytopenia (ITP) at 2019 ASH Annual Meeting

Dec

07

UCB Addresses Urgent Unmet Need for Patients with Epilepsy

As UCB attends the 2019 American Epilepsy Society meeting in Baltimore, Maryland this week, Mike Davis, Head of Neurology in the U.S., talks about the long way to go in managing epilepsy, and how UCB is committed to closing this gap by bringing new solutions to market. Read the article on LinkedIn.

Dec

06

Press Release: Bimekizumab Phase 3 Psoriasis Study Demonstrates Superiority Versus Humira®

Bimekizumab Phase 3 Psoriasis Study Demonstrates Superiority Versus Humira®

Dec

05

Press Release: UCB Presents New Data Demonstrating Commitment to Epilepsy at 2019 American Epilepsy Society Meeting

• 14 scientific presentations will cover UCB’s pipeline assets, epilepsy-specific research, and licensed medicines, including NAYZILAM, now available for the acute treatment of seizure clusters in epilepsy patients 12 years of age and older
• Friday evening symposium on “Epilepsy Treatment Update for Patients Suffering from Seizure Clusters” includes Epilepsy Foundation’s project on seizure emergencies and a panel discussion on the misconceptions around seizure clusters